Thanks! So it seems one can find it if one searches for "ME/CFS" but not when one searches for "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" or "Myalgic Encephalomyelitis".
-
New Forum Software Installed (Still a few issues but reopening the forum) More details.
The LIFT trial (OMF) - Pyridostigmine (mestinon) and Low Dose Naltrexone (LDN)
- Thread starter LesPig
- Start date
-
- Tags
- ldn lift trial mestinon omf
Thanks! So it seems one can find it if one searches for "ME/CFS" but not when one searches for "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" or "Myalgic Encephalomyelitis".
Pyridostigmine and low-dose naltrexone for ME/CFS: study protocol for the Life Improvement Trial (LIFT), a randomized, double-blind, placebo-controlled clinical trial
Danielle Meadows, Johanna Squires, Joshua Dibble, Shreya Palwayi, Donna Felsenstein, Linda Tannenbaum, Peng Li, Wenzhong Xiao, Jonas Bergquist, David Systrom
Background
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic disease with no FDA-approved treatments. This report describes a protocol for the Life Improvement Trial (LIFT), a randomized, double-blind, placebo-controlled clinical trial investigating the impact of low-dose naltrexone (LDN) and pyridostigmine (Mestinon) on physiological response, symptoms, and functionality of ME/CFS patients.
Methods
Participants (target n = 160) are recruited through clinics at Massachusetts General Hospital and Brigham and Women’s Hospital, and through Open Medicine Foundation’s StudyME registry. They are then randomized into one of four arms: LDN/pyridostigmine, LDN/placebo, placebo/pyridostigmine, placebo/placebo. Treatment is administered for 13 weeks after an initial screening period of up to 4 weeks. Primary outcomes are FUNCAP-55 score, peak oxygen utilization, heart rate recovery, and oxygen uptake efficiency slope. Secondary outcomes are scores from DSQ-PEM and PROMIS-29 surveys, DANA Brain Vital score, step count, heart rate, and heart rate variability.
Discussion
The results of this trial will provide novel insights into the efficacy of and predictors of response to LDN and pyridostigmine in ME/CFS. This may inform future treatment strategies for ME/CFS. The trial will also validate what primary and secondary outcomes to use in similar clinical trials.
Trial registration
This trial was registered on clinicaltrials.gov (NCT06366724) on April 16, 2024.
Link | PDF (Preprint: Research Square) [Open Access]
Danielle Meadows, Johanna Squires, Joshua Dibble, Shreya Palwayi, Donna Felsenstein, Linda Tannenbaum, Peng Li, Wenzhong Xiao, Jonas Bergquist, David Systrom
Background
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic disease with no FDA-approved treatments. This report describes a protocol for the Life Improvement Trial (LIFT), a randomized, double-blind, placebo-controlled clinical trial investigating the impact of low-dose naltrexone (LDN) and pyridostigmine (Mestinon) on physiological response, symptoms, and functionality of ME/CFS patients.
Methods
Participants (target n = 160) are recruited through clinics at Massachusetts General Hospital and Brigham and Women’s Hospital, and through Open Medicine Foundation’s StudyME registry. They are then randomized into one of four arms: LDN/pyridostigmine, LDN/placebo, placebo/pyridostigmine, placebo/placebo. Treatment is administered for 13 weeks after an initial screening period of up to 4 weeks. Primary outcomes are FUNCAP-55 score, peak oxygen utilization, heart rate recovery, and oxygen uptake efficiency slope. Secondary outcomes are scores from DSQ-PEM and PROMIS-29 surveys, DANA Brain Vital score, step count, heart rate, and heart rate variability.
Discussion
The results of this trial will provide novel insights into the efficacy of and predictors of response to LDN and pyridostigmine in ME/CFS. This may inform future treatment strategies for ME/CFS. The trial will also validate what primary and secondary outcomes to use in similar clinical trials.
Trial registration
This trial was registered on clinicaltrials.gov (NCT06366724) on April 16, 2024.
Link | PDF (Preprint: Research Square) [Open Access]
Utsikt
Senior Member (Voting Rights)
Subjects who complete the trial are also permitted to keep their Garmin watch.
Garmin Vivosmart 5 go for ~$150. They receive up to an additional $250 if they complete all steps.
$400 per person seems like a relatively cheap way to hedge against dropouts considering the cost of running trials.
I guess that depends whether they are looking for immediate effects or gradual or long term effects. If only immediate effects, such as testing a pain killer, then rotating them makes sense. If the treatment is aimed at, for example, long term elimination of PEM that only be judged over several years, then switching would make it impossible to tell which drug was effective.